4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0001577014-26-000012
Director sold 504,695 shares at an average $21.23 ($10,712,550)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Rhodes Jason P Director | 2026-06-26 | Sale 10b5-1 | −162,954 | $21.28 | $3,467,661 | 4,579,456 | I |
| Rhodes Jason P Director | 2026-06-26 | Sale 10b5-1 | −81,903 | $21.28 | $1,742,896 | 1,396,475 | I |
| Rhodes Jason P Director | 2026-06-26 | Sale 10b5-1 | −64,411 | $21.28 | $1,370,666 | 1,016,633 | I |
| Rhodes Jason P Director | 2026-06-29 | Sale 10b5-1 | −102,969 | $21.14 | $2,176,765 | 4,476,487 | I |
| Rhodes Jason P Director | 2026-06-29 | Sale 10b5-1 | −51,756 | $21.14 | $1,094,122 | 1,344,719 | I |
| Rhodes Jason P Director | 2026-06-29 | Sale 10b5-1 | −40,702 | $21.14 | $860,440 | 975,931 | I |
| Open-market sales · 504,695 sh · avg $21.23 · $10,712,550 | |||||||
Loading xslF345X06/form4-06302026_110610.xml…